These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 15599323)

  • 1. A truncated-dose regimen of daclizumab for prevention of acute rejection in kidney transplant recipients: a single-center experience.
    Soltero L; Carbajal H; Sarkissian N; Khan AJ; Brennan S; Gonzalez JM; Truong LD; Suki WN
    Transplantation; 2004 Nov; 78(10):1560-3. PubMed ID: 15599323
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Daclizumab (humanized anti-IL2Ralpha mAb) prophylaxis for prevention of acute rejection in renal transplant recipients with delayed graft function.
    Bumgardner GL; Ramos E; Lin A; Vincenti F;
    Transplantation; 2001 Aug; 72(4):642-7. PubMed ID: 11544424
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Two doses of daclizumab in conjunction with low-dose cyclosporine, mycophenolate mofetil and steroids resulted in a low incidence of acute rejection after renal transplantation.
    Ekberg H; Persson NH; Källen R; Gül-Baykurt N
    Scand J Immunol; 2003 Dec; 58(6):670-7. PubMed ID: 14636424
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A single-dose daclizumab induction protocol in renal allograft recipients: a Chinese single center experience.
    Ji SM; Li LS; Cheng Z; Cheng DR; Sun QQ; Chen JS; Sha GZ; Liu ZH
    Transplant Proc; 2007 Jun; 39(5):1396-401. PubMed ID: 17580147
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Two-dose daclizumab regimen in simultaneous kidney-pancreas transplant recipients: primary endpoint analysis of a multicenter, randomized study.
    Stratta RJ; Alloway RR; Lo A; Hodge E
    Transplantation; 2003 Apr; 75(8):1260-6. PubMed ID: 12717213
    [TBL] [Abstract][Full Text] [Related]  

  • 6. One-year outcomes in simultaneous kidney-pancreas transplant recipients receiving an alternative dosing regimen of daclizumab.
    Stratta RJ; Alloway RR; Lo A; Hodge EE;
    Transplant Proc; 2004 May; 36(4):1080-1. PubMed ID: 15194375
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reduction of acute renal allograft rejection by daclizumab. Daclizumab Double Therapy Study Group.
    Nashan B; Light S; Hardie IR; Lin A; Johnson JR
    Transplantation; 1999 Jan; 67(1):110-5. PubMed ID: 9921806
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Two-dose daclizumab induction therapy in 209 liver transplants: a single-center analysis.
    Sellers MT; McGuire BM; Haustein SV; Bynon JS; Hunt SL; Eckhoff DE
    Transplantation; 2004 Oct; 78(8):1212-7. PubMed ID: 15502722
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A prospective, randomized, multicenter study evaluating the safety and efficacy of two dosing regimens of daclizumab compared to no antibody induction in simultaneous kidney-pancreas transplantation: results at 3 years.
    Stratta RJ; Alloway RR; Lo A; Hodge EE
    Transplant Proc; 2005 Oct; 37(8):3531-4. PubMed ID: 16298651
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of Daclizumab in a high-risk renal transplant population.
    Meier-Kriesche HU; Kaza H; Palekar SS; Friedman GS; Mulgaonkar SP; Ojo AO; Kaplan B
    Clin Transplant; 2000 Oct; 14(5):509-13. PubMed ID: 11048998
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Results of 3-year phase III clinical trials with daclizumab prophylaxis for prevention of acute rejection after renal transplantation.
    Bumgardner GL; Hardie I; Johnson RW; Lin A; Nashan B; Pescovitz MD; Ramos E; Vincenti F;
    Transplantation; 2001 Sep; 72(5):839-45. PubMed ID: 11571447
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cyclosporine-sparing effects of daclizumab in renal allograft recipients.
    Ingle GR; Moudgil A; Vo A; Jordan SC
    Am J Health Syst Pharm; 2005 Feb; 62(4):391-6. PubMed ID: 15745891
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Daclizumab: a review of its use in the prevention of acute rejection in renal transplant recipients.
    Wiseman LR; Faulds D
    Drugs; 1999 Dec; 58(6):1029-42. PubMed ID: 10651389
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multicenter survey of daclizumab induction in simultaneous kidney-pancreas transplant recipients.
    Bruce DS; Sollinger HW; Humar A; Sutherland DE; Light JA; Kaufman DB; Alloway RR; Lo A; Stratta RJ
    Transplantation; 2001 Nov; 72(10):1637-43. PubMed ID: 11726823
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of daclizumab, an interleukin 2 receptor antibody, to anti-thymocyte globulin-Fresenius induction therapy in kidney transplantation.
    Abou-Jaoude MM; Ghantous I; Almawi WY
    Mol Immunol; 2003 Jul; 39(17-18):1083-8. PubMed ID: 12835081
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Two-dose basiliximab compared with two-dose daclizumab in renal transplantation: a clinical study.
    Lin M; Ming A; Zhao M
    Clin Transplant; 2006; 20(3):325-9. PubMed ID: 16824149
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Limited-dose Daclizumab versus Basiliximab: a comparison of cost and efficacy in preventing acute rejection.
    Pham K; Kraft K; Thielke J; Oberholzer J; Sankary H; Testa G; Benedetti E
    Transplant Proc; 2005 Mar; 37(2):899-902. PubMed ID: 15848569
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Experience with daclizumab in liver transplantation: renal transplant dosing without calcineurin inhibitors is insufficient to prevent acute rejection in liver transplantation.
    Hirose R; Roberts JP; Quan D; Osorio RW; Freise C; Ascher NL; Stock PG
    Transplantation; 2000 Jan; 69(2):307-11. PubMed ID: 10670644
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Zenapax versus OKT-3 prophylaxis in immunologically high-risk kidney transplant recipients.
    Lácha J; Símová M; Nosková L; Teplan V; Vítko S
    Transplant Proc; 2001 May; 33(3):2273-4. PubMed ID: 11377526
    [No Abstract]   [Full Text] [Related]  

  • 20. Zenapax (daclizumab) reduces the incidence of acute rejection episodes and improves patient survival following renal transplantation. No 14874 and No 14393 Zenapax Study Groups.
    Ekberg H; Bäckman L; Tufveson G; Tydén G
    Transplant Proc; 1999; 31(1-2):267-8. PubMed ID: 10083102
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.